GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

In 2021, GSK and Oxford established the Institute of Molecular and Computational Medicine to drive forward the research and ...

IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...

GSK has claimed its second breakthrough designation ... stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the drug for this use last year.

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...